Drugs / Evofosfamide
Evofosfamide
Trials 27
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-10-31 | Ascentawits Pharmaceuticals, Ltd | Results 艾欣达伟在国际期刊发表研究成果详细阐述TH-302（AST-006）在治疗PARP抑制剂耐药性癌症方面的显著疗效 ascentawits.com ↗
研究结果表明， TH-302 在临床前实验中已被证实能够在卵巢癌、肺癌、胰腺癌等患者对 PARP 抑制剂产生耐药性后，依然发挥显著的抗肿瘤活性。 |
| 2021-11-15 | ImmunoGenesis | Results Data from ImmunoGenesis’ Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference immunogenesis.com ↗
The researchers concluded that evofosfamide and DC101 utilize unique yet complementary mechanisms to improve the survival of mice challenged with pancreatic or prostate tumors. |
| 2021-06-16 | ImmunoGenesis | Results ImmunoGenesis Announces Publication of Phase 1 Data on its Hypoxia-Reversal Agent Highlighting Efficacy and Genetic Expression Correlatives in Advanced Cancer immunogenesis.com ↗
In addition, a clear biomarker picture emerged with pre-existing immune gene signatures correlating with response to therapy and hypermetabolic signatures predicting progression. |
| 2015-12-07 | Merck KGaA, Darmstadt, Germany | Results Merck KGaA, Darmstadt, Germany, Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer prnewswire.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-31 | Ascentawits Pharmaceuticals, Ltd | 艾欣达伟在国际期刊发表研究成果详细阐述TH-302（AST-006）在治疗PARP抑制剂耐药性癌症方面的显著疗效 ascentawits.com ↗ |
| 2021-11-15 | ImmunoGenesis | Data from ImmunoGenesis’ Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference immunogenesis.com ↗ |
| 2021-06-16 | ImmunoGenesis | ImmunoGenesis Announces Publication of Phase 1 Data on its Hypoxia-Reversal Agent Highlighting Efficacy and Genetic Expression Correlatives in Advanced Cancer immunogenesis.com ↗ |
| 2015-12-07 | Merck KGaA, Darmstadt, Germany | Merck KGaA, Darmstadt, Germany, Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer prnewswire.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | evofosfamide | “A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in...” PMID 27535748 ↗ Aug 20165“Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.” PMID 34190375 ↗ Jul 2021 |
| Known as | EVO | “Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.” PMID 34190375 ↗ Jul 2021 |
| Known as | Evofosfamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL260046 ↗ |
| Known as | HAP-302 | ChEMBL registry synonym — accepted as the source's own label CHEMBL260046 ↗ |
| Known as | TH-302 | “The goal of this study is to provide continuation therapy with TH-302 to patients with soft tissue sarcomas who obtained response or stabilization of disease with prior...” NCT02712567 ↗24“The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).” NCT01721941 ↗ |
| Known as | TH-302 (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophos-phate | “TH-302 (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophos-phate is a nitroimidazole-linked prodrug of a brominated version of isophosphoramide...” NCT02433639 ↗ |
| Modality | Other / unclassified | “TH-302 is an investigational hypoxia-activated prodrug” PMID 25512461 ↗ Dec 2014 |
| Route | Intravenous | “TH-302 will be administered by IV infusion over 30-60 minutes” NCT00742963 ↗ |